In 2018, the market size of Chinese diabetes medication sector was estimated to be about 51.8 billion yuan with oral hypoglycemic drugs as the major revenue generator. Its market share would gradually decline, whereas glucagon-like peptide 1 receptor agonists (GLP-1 RAs) were expected to raise its market presence significantly to 21 percent by 2030. In 2017, Beijing included Novo Nordisk’s Liragultide – the bestselling GLP-1 RA medication in China – into the national insurance list for reimbursement, leading to a surge in sales revenue of the product in the country.
…. more: Statista.com (Quelle/Source)